RecruitingPhase 1/2

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

United States10 participantsStarted 2025-09-16

Plain-language summary

This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Serum creatinine clearance less than 30 ml/min (eGFR).
✕. Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.
✕. Platelets \< 50 × 10\^9/L without transfusions
✕. ANC \< 0.75 × 10\^9/L without growth factors

Change in Hepcidin Levels

Timeframe: 30 days

NCT IDNCT07281781

SponsorUniversity of California, Irvine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

Chao Family Comprehensive Cancer Center University of California, Irvine